Another possible deal between two of the world's top pharmaceutical companies was announced this week when Shire Plc. (Nasdaq: SHPG) made an unsolicited offer of $30.6 billion for Baxalta Inc. (NYSE: BXLT).
Money Morning Defense & Tech Specialist Michael A. Robinson has been following this trend since 2014. He knew the world's top pharmaceutical companies would continue their M&A binge, and he recommended an investment to play that wave.
Robinson's pick has already climbed 17.6% this year and still has plenty of room to run...
Another possible deal between two of the world's top pharmaceutical companies was announced this week when Shire Plc. (Nasdaq: SHPG) made an unsolicited offer of $30.6 billion for Baxalta Inc. (NYSE: BXLT).
Money Morning Defense & Tech Specialist Michael A. Robinson has been following this trend since 2014. He knew the world's top pharmaceutical companies would continue their M&A binge, and he recommended an investment to play that wave.
Robinson's pick has already climbed 17.6% this year and still has plenty of room to run...
The pharmaceutical industry saw record-setting M&A activity in the first quarter of 2015.
According to PricewaterhouseCoopers, the "life sciences" field had 35 deals in Q1 2015. Those deals totaled $166.3 billion. That's more money than was spent during the entire year in 2014, when $150.1 billion was spent. In Q1 2014, just $46.5 billion was spent.
Money Morning's Defense and Tech Specialist Michael Robinson has been recommending a way to profit from the M&A boom throughout 2015.
